Sarepta Therapeutics, INC. 8-K Filing
Ticker: SRPT · Form: 8-K · Filed: Nov 3, 2025 · CIK: 873303
Sentiment: neutral
Filing Stats: 513 words · 2 min read · ~2 pages · Grade level 10.5 · Accepted 2025-11-03 16:18:27
Key Financial Figures
- $0.0001 — nge on which registered Common Stock, $0.0001 par value per share SRPT Nasdaq Glo
Filing Documents
- srpt-20251103.htm (8-K) — 46KB
- srpt-ex99_1.htm (EX-99.1) — 877KB
- 0001193125-25-262591.txt ( ) — 1070KB
- srpt-20251103.xsd (EX-101.SCH) — 23KB
- srpt-20251103_htm.xml (XML) — 4KB
02. Results of Operations and Financial Condition
Item 2.02. Results of Operations and Financial Condition. On November 3, 2025, Sarepta Therapeutics, Inc. issued a press release announcing its financial results for the quarter ended September 30, 2025. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in Item 2.02 of this Form 8-K (including Exhibit 99.1) shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits Exhibit Number Description 99.1 Press Release dated November 3, 2025 104 The cover page from this Current Report on Form 8-K of Sarepta Therapeutics, Inc., formatted in Inline XBRL and included as Exhibit 101
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Sarepta Therapeutics, Inc. Date: November 3, 2025 By: /s/ Douglas S. Ingram Douglas S. Ingram Chief Executive Officer